Canada Animal Healthcare - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The canada animal healthcare market size is expected to increase from USD 2.98 billion in 2025 to USD 3.19 billion in 2026 and reach USD 4.45 billion by 2031, growing at a CAGR of 6.92% over 2026-2031. This report is Segmented by Product (Therapeutics, Diagnostics), Animal Type (Companion Animals, Equine, Livestock), Route of Administration (Oral, Parenteral, Topical, Other Routes), and End User (Veterinary Hospitals & Clinics, Academic & Research Institutes, Point-Of-Care / In-House Settings). The Market Forecasts are Provided in Terms of Value (USD).

Canada Animal Healthcare Market Trends and Insights

Rising Pet Ownership & Premiumization of Companion-Animal Care

Sixty percent of Canadian households owned a dog or cat in 2024, underpinning steady demand for core vaccinations and chronic-disease management. Premiumization is visible in the rapid uptake of monoclonal antibodies such as Librela, which command monthly prices above CAD 100 yet reduce long-term NSAID exposure and renal risk. Annual household pet spending reached CAD 9.3 billion in 2023, with veterinary services absorbing the largest share. Ontario’s 2024 Veterinary Professionals Act widened the telemedicine scope, enabling remote follow-ups that support bundled care plans. Urban clinics now package diagnostics, therapeutics, and digital monitoring to differentiate in competitive metro areas, while rural large-animal clients remain underserved.

Rapid Adoption of Advanced Diagnostics (POCT & Molecular)

Point-of-care platforms compress turnaround times from days to minutes, enabling same-visit therapy decisions that lift compliance and clinic throughput. IDEXX’s inVue Dx cellular analyzer, launched in November 2024, delivers AI-assisted cytology in 10 minutes, displacing manual microscopy in routine cases. The Catalyst Pancreatic Lipase Test provides quantitative pancreatitis results within 10 minutes, outperforming reference-lab assays that require up to 48 hours. On the production-animal side, CFIA’s National Centre for Foreign Animal Disease upgraded to Oxford Nanopore and Illumina sequencing between 2023 and 2026, enabling real-time pathogen characterization during outbreaks. Prairie Diagnostic Services cut Salmonella serotyping turnaround from four weeks to 24 hours by adopting Nanopore sequencing in 2024. Regulatory guidance from the College of Veterinarians of Ontario in December 2024 acknowledged the innovation speed yet flagged validation and liability gaps for AI-enabled devices.

High Cost of Veterinary Services & Therapeutics

Veterinary service prices have risen faster than general inflation, driven by labor shortages, diagnostic-equipment capex, and pharmaceutical price hikes, pushing routine exams with vaccinations to above CAD 300 and emergency visits past CAD 2,000. Premium biologics such as Librela and Solensia cost CAD 100-150 per month, limiting access for multi-pet households. Rural communities face compounded burdens because a shortage of veterinarians forces long travel or defers care, especially in large-animal sectors. The Competition Bureau’s October 2024 study highlighted exclusive distribution agreements as cost inflators and recommended pharmacist dispensing, which Ontario, Alberta, and Quebec have begun adopting. Until insurance penetration or public subsidies expand, discretionary categories, such as dental, behavioral, and wellness diagnostics, will see volume constraints.

Other drivers and restraints analyzed in the detailed report include:

• National FMD & HPAI Vaccine-Bank Investments Boosting Biologics Demand
• Growth in Pet Insurance Penetration Expanding Spend Capacity
• Counterfeit & Grey-Market Medicines

Segment Analysis

Therapeutics commanded 60.4% of Canada animal healthcare market share in 2025, supported by vaccines, parasiticides, anti-infectives, and monoclonal antibodies. Diagnostics captured the balance but are set to grow at a 7.86% CAGR through 2031, the strongest category trajectory. Vaccine revenue remains resilient across both companion and production animals; however, innovation momentum has shifted toward autogenous and recombinant platforms that target farm-specific pathogens. Parasiticides evolved from spot-ons to flavored chewables such as Simparica Trio and NexGard PLUS, blending flea, tick, heartworm, and intestinal-parasite protection in one dose. Diagnostics growth hinges on point-of-care immunoassays and AI-enabled imaging that shorten decision cycles. IDEXX’s inVue Dx automates cytology in primary-care clinics, while molecular platforms anchor surveillance in production-animal sectors, underscoring how diagnostics now set the pace for innovation.

Diagnostics generate sticky consumable revenue and lock practices into proprietary ecosystems, insulating suppliers from price competition. Immunodiagnostic tests dominate companion-animal practice, but molecular assays and next-generation sequencing are penetrating livestock surveillance, aided by CFIA’s genomics upgrades. Digital pathology and AI-driven radiology analysis remain nascent yet represent the next wave of diagnostic differentiation.

Dogs and cats generated 56.1% of 2025 revenue, reflecting Canada’s 7.9 million dogs and 8.5 million cats and the premiumization trend in urban centers. Poultry is set for the fastest growth at a 7.12% CAGR, driven by HPAI surveillance, autogenous-vaccine adoption, and biosecurity spend in British Columbia’s Fraser Valley. Equine and livestock segments provide stable demand for reproductive vaccines and joint-health products, but face workforce shortages that cap service capacity.

Companion-animal spend is concentrated in specialty diagnostics and monoclonal antibodies, with Mars-owned VCA Canada operating more than 120 hospitals that aggregate complex-care demand. Poultry urgency is shaped by export-market risk; Canada’s HPAI Vaccination Task Force continues to assess trade-partner acceptance before endorsing routine immunization. Livestock growth depends on competitive export access and ongoing antimicrobial-use reductions, nudging producers toward preventive biologics and probiotics.

Complete Report Scope:

• By Product
  • Therapeutics
    • Vaccines
    • Parasiticides
    • Anti-infectives
    • Medical Feed Additives
    • Monoclonal Antibodies & Biologics
  • Diagnostics
    • Immunodiagnostic Tests
    • Molecular Diagnostics (PCR, qPCR, NGS)
    • Diagnostic Imaging
    • Clinical Chemistry & Hematology
    • Digital Pathology & AI Platforms
• By Animal Type
  • Companion Animals
  • Equine
  • Livestock
• By Route of Administration
  • Oral
  • Parenteral
  • Topical
  • Other Routes
• By End User
  • Veterinary Hospitals & Clinics
  • Academic & Research Institutes
  • Point-of-Care / In-House Settings

List of Companies Covered in this Report:

• Bimeda Canada
• Boehringer Ingelheim
• Ceva
• Covetrus
• Covetrus Canada
• Dechra Pharmaceuticals
• Elanco Canada
• Heska Canada
• IDEXX
• Merck
• Phibro Animal Health
• Sentinel Veterinary Diagnostics
• Trupanion Canada
• VCA Canada
• Vet Strategy
• Vetoquinol
• Virbac
• Zoetis Canada

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support